Diabetes knows no age and affects millions of individuals. Preventing diabetes in children is increasingly becoming a major health policy concern and focus. The objective of this study is to project the number of children, aged 0-17 years, with diagnosed diabetes in the United States through 2030, accounting for changing demography, and diabetes and obesity prevalence rates. The study team combined historic diabetes and obesity prevalence data with US child population estimates and projections. A times-series regression model was used to forecast future diabetes prevalence and to account for the relationship between the forecasted diabetes prevalence and the lagged prevalence of childhood obesity. Overall, the prevalence of diagnosed diabetes is projected to increase 67% from 0.22% in 2010 to 0.36% in 2030. Lagged obesity prevalence in Hispanic boys and non-Hispanic black girls was significantly associated with increasing future diabetes prevalence. The study results showed that a 1% increase in obesity prevalence among Hispanic boys from the previous year was significantly associated with a 0.005% increase in future prevalence of diagnosed diabetes in children (P ≤ 0.01). Likewise, a unit increase in obesity prevalence among non-Hispanic black girls was associated with a 0.003% increase in future diabetes prevalence (P < 0.05). Obesity rates for other race/ethnicity combinations were not associated with increasing future diabetes prevalence. To mitigate the continued threat posed by diabetes, serious discussions need to focus on the pediatric population, particularly non-Hispanic black girls and Hispanic boys whose obesity trends show the strongest associations with future diabetes prevalence in children.

Download full-text PDF

Source
http://dx.doi.org/10.1089/pop.2014.0084DOI Listing

Publication Analysis

Top Keywords

obesity prevalence
24
diabetes prevalence
24
future diabetes
20
diabetes
16
diagnosed diabetes
16
prevalence
15
prevalence diagnosed
12
diabetes children
12
hispanic boys
12
non-hispanic black
12

Similar Publications

Objectives: Despite substantial evidence that visceral obesity is an epidemiological risk factor for hyperuricemia (HUA), studies on the connection between the Metabolic Score for Visceral Fat (METS-VF) and HUA remain insufficient. This research focused on METS-VF's potential role as a risk factor for HUA.

Methods: Notably, 8,659 participants from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018 were enrolled in this study.

View Article and Find Full Text PDF

While the prevalence of overweight and obesity is rising in Africa, the practice of bariatric surgery remains limited in our country, Cameroon. Weight loss outcomes following sleeve gastrectomy (SG), the most widely used bariatric surgery technique worldwide, have not yet been studied in our context. The medical records of all patients who underwent SG in our surgery department between January 1, 2016, and September 30, 2020, were reviewed retrospectively.

View Article and Find Full Text PDF

Introduction: arterial hypertension (AH) may persist beyond three months postpartum after preeclampsia, increasing the long-term risk of cardiovascular complications. The purpose of this study is to describe the epidemiological aspects and factors associated with persistent hypertension following preeclampsia.

Methods: we conducted a longitudinal descriptive study, from January 2022 to June 2023.

View Article and Find Full Text PDF

Background: Clonal hematopoiesis of indeterminate potential (CHIP) is the age-related presence of expanded somatic clones secondary to leukemogenic driver mutations and is associated with cardiovascular (CV) disease and mortality. We sought to evaluate relationships between CHIP with cardiometabolic diseases and incident outcomes in high-risk individuals.

Methods: CHIP genotyping was performed in 8469 individuals referred for cardiac catheterization at Duke University (CATHGEN study) to identify variants present at a variant allele fraction (VAF) ≥2%.

View Article and Find Full Text PDF

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing global health concern which is driven by the increasing prevalence of diabetes and obesity. MAFLD is characterized by excessive fat accumulation in the liver, which encompasses a range of conditions, from simple hepatic steatosis to more severe forms. This condition is associated with various complications, including chronic kidney disease (CKD), Cardiovascular Disease (CVD), liver cirrhosis, and even malignancy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!